James McMahon
Family · Cherry Point, NCNPI 1275503146
Payments from drug & device makers
Across 212 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$717
- AbbVie$333
- Amgen$279
- Lilly USA, LLC$273
- AstraZeneca$177
- Novartis$176
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,728100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 47 | $717 |
| AbbVie | 19 | $333 |
| Amgen(2 entities) | 16 | $279 |
| Lilly USA, LLC | 14 | $273 |
| AstraZeneca | 7 | $177 |
| Novartis | 9 | $176 |
| GSK | 10 | $152 |
| Xeris Pharmaceuticals, Inc. | 8 | $150 |
| Kowa Pharmaceuticals America, Inc. | 10 | $137 |
| Pfizer | 8 | $129 |
| Eisai Inc. | 1 | $123 |
| Johnson & Johnson | 7 | $109 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $95 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $89 |
| Otsuka America Pharmaceutical, Inc. | 4 | $83 |
| Astellas Pharma US Inc | 4 | $77 |
| Boehringer Ingelheim | 4 | $76 |
| E.r. Squibb & Sons, L.L.C. | 5 | $70 |
| Abbott | 4 | $66 |
| Merck | 4 | $63 |
| Exact Sciences | 3 | $61 |
| Dexcom, Inc. | 3 | $47 |
| Amarin Pharma, Inc. | 3 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| Bayer | 2 | $30 |
| Edwards Lifesciences | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Leqembi$123
How this compares
$3,728 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 61 | $44,193 |
| TrulicityDulaglutide | 24 | $32,487 |
| JardianceEmpagliflozin | 20 | $18,311 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $16,349 |
| MounjaroTirzepatide | 14 | $15,312 |
| MyrbetriqMirabegron | 23 | $12,581 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $10,875 |
| JanuviaSitagliptin Phosphate | 15 | $9,741 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 13 | $6,792 |
| Rosuvastatin Calcium | 118 | $3,625 |
| LivaloPitavastatin Calcium | 11 | $3,604 |
| Memantine Hcl | 34 | $2,867 |
| Gabapentin | 117 | $2,064 |
| Famotidine | 96 | $2,050 |
| Esomeprazole Magnesium | 25 | $1,967 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $273 | $47,79938 claims |
| PfizerEliquis | $129 | $44,19361 claims |
| MerckJanumet, Januvia | $63 | $26,09028 claims |
| Boehringer IngelheimJardiance | $76 | $18,31120 claims |
| Astellas Pharma US IncMyrbetriq | $77 | $12,58123 claims |
| GSKTrelegy Ellipta | $152 | $10,87516 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $137 | $3,60411 claims |
| AbbVieSynthroid | $333 | $50911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.
Other family in Cherry Point
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.